businesswire.com · 25 jun

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos' proprietary iLution platform, a novel ophthalmic drug-delivery syste.

zacks.com · 5 jun

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.

businesswire.com · 12 may

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

zacks.com · 30 abr

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.

seekingalpha.com · 29 abr

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

zacks.com · 29 abr

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com · 29 abr

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.

businesswire.com · 29 abr

Glaukos Announces First Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.